OCALA, Fla.--(BUSINESS WIRE)--AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today issued a presentation in connection with its upcoming 2024 Annual Meeting of Stockholders the (“Annual Meeting”), presently scheduled for December 17, 2024.

佛罗里达州奥卡拉市——（商业新闻短讯）——AIM ImmunoTech Inc.（纽约证券交易所美国代码：AIM）（“AIM”或“公司”）今天就即将举行的2024年股东年会（“年会”）发表了一份演讲，该年会目前定于2024年12月17日举行。

Highlights of the presentation include the following:

演讲的亮点包括：

AIM is executing on its strategy to create long-term value for patients and shareholders by driving clinical development programs in areas with critical unmet needs, especially in the high-value pancreatic cancer space.

AIM正在执行其战略，通过推动临床开发计划在关键需求未得到满足的领域，特别是在高价值胰腺癌领域，为患者和股东创造长期价值。

AIM’s clinical pipeline has significant momentum and is laying the groundwork for commercialization opportunities by delivering exciting data across clinical trials, including in two ongoing studies with AstraZeneca and Merck. These commercialization opportunities are what can drive substantial value creation..

AIM的临床渠道势头强劲，正在通过临床试验（包括阿斯利康和默克正在进行的两项研究）提供令人兴奋的数据，为商业化机会奠定基础。这些商业化机会可以推动实质性的价值创造。。

If elected, the Activist Group intends to seek over $5 million from AIM to pay for its previous takeover attempts and litigation against the Company that the Activist Group lost, in addition to any expenses incurred in connection with its solicitation for this year’s Annual Meeting. The Activist Group disclosed that it does not intend to put this personal reimbursement to a shareholder vote..

如果当选，维权组织打算向AIM寻求500多万美元，以支付之前的收购企图和维权组织对该公司的诉讼损失，以及与今年年会招标相关的任何费用。该维权组织透露，它不打算将这笔个人报销交给股东投票表决。。

Despite AIM’s best attempts at a constructive settlement that would put two of the Activist Group’s nominees on the Board, the Activist Group has continued to insist it receive upwards of $8 million to make all litigants whole in connection with certain litigation as part of any resolution – this represents more than 50% of AIM’s current market capitalization..

尽管AIM尽最大努力达成建设性解决方案，将维权组织的两名提名人列入董事会，但维权组织仍坚持收取800多万美元，以使所有与某些诉讼有关的诉讼当事人成为任何决议的一部分-这占AIM目前市值的50%以上。。

The Activist Group has indicated it would likely appoint Robert Chioini as interim CEO while the Board runs a succession process should its nominees gain control of the Board. Mr. Chioini was fired as CEO of Rockwell Medical in 2018 because of his “sustained mismanagement” of the company and “blatant disregard for shareholder concerns,” according to a Rockwell Medical spokesperson.1 Following his termination, Mr.

该激进组织表示，如果提名人获得董事会控制权，该组织可能会任命罗伯特·奇奥尼（RobertChioini）为临时首席执行官，同时董事会将进行继任程序。罗克韦尔医疗公司发言人表示，2018年，奇奥尼先生被罗克韦尔医疗公司解雇，原因是他对公司的“持续管理不善”以及“公然无视股东的担忧”。

Chioini “refuse[d] to accept the decision” and, without authorization, filed a Current Report on Form 8-K on the company’s behalf “making various assertions regarding the five independent directors who voted in favor of Mr. Chioini’s removal.”2 This behavior indicates, in our view, that Mr. Chioini is unfit to serve as a public company director – let alone CEO..

Chioini“拒绝接受这一决定”，并在未经授权的情况下，代表公司以表格8-K提交了一份最新报告，“对投票支持Chioini先生罢免的五名独立董事做出了各种断言。”2我们认为，这种行为表明，Chioini先生不适合担任上市公司董事，更不用说首席执行官了。。

AIM encourages shareholders to review its presentation and vote FOR the Board’s incumbent candidates – Stewart L. Appelrouth, Nancy K. Bryan, Thomas K. Equels and Dr. William M. Mitchell – on the WHITE universal proxy card.

AIM鼓励股东审查其陈述，并在白色环球代理卡上投票给董事会现任候选人斯图尔特·阿佩鲁思（StewartL.Appelrouth）、南希·K·布莱恩（NancyK.Bryan）、托马斯·K·埃奎尔斯（ThomasK.Equels）和威廉·米切尔（WilliamM.Mitchell）。

For more information on how to vote, visit: www.SafeguardAIM.com.

有关如何投票的更多信息，请访问：www.SafeguardAIM.com。

WE URGE YOU TO COMPLETE, SIGN, DATE AND RETURN THE WHITE UNIVERSAL PROXY CARD AND MAIL IT PROMPTLY IN THE POSTAGE-PAID ENVELOPE PROVIDED, OR VOTE BY INTERNET AS INSTRUCTED ON THE WHITE UNIVERSAL PROXY CARD, WHETHER OR NOT YOU PLAN TO VIRTUALLY ATTEND THE ANNUAL MEETING.

我们敦促您填写、签署、注明日期并退还白色通用代理卡，并立即将其邮寄到提供的邮资已付信封中，或按照白色通用代理卡上的指示通过互联网进行投票，无论您是否计划实际参加年会。

THE BOARD RECOMMENDS A VOTE “FOR” ALL OF OUR BOARD’S CANDIDATES (STEWART L. APPELROUTH, NANCY K. BRYAN, THOMAS K. EQUELS AND DR. WILLIAM M. MITCHELL) ON PROPOSAL 1 USING THE WHITE UNIVERSAL PROXY CARD.

董事会建议对所有董事会候选人（斯图尔特·L·阿佩鲁思、南希·K·布莱恩、托马斯·K·埃奎尔斯和威廉·M·米切尔博士）使用白色通用代理卡对提案1进行投票。

About AIM ImmunoTech Inc.

关于AIM ImmunoTech Inc。

AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s lead product is a first-in-class investigational drug called Ampligen® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system..

AIM ImmunoTech Inc.是一家免疫制药公司，专注于研究和开发治疗多种癌症，免疫疾病和病毒性疾病的疗法，包括新型冠状病毒肺炎。该公司的主导产品是一种名为Ampligen®（rintatolimod）的一流研究药物，是一种dsRNA和高选择性TLR3激动剂免疫调节剂，在全球重要癌症，病毒性疾病和免疫系统疾病的临床试验中具有广谱活性。。

For more information, please visit aimimmuno.com and connect with the Company on X, LinkedIn, and Facebook.

有关更多信息，请访问aimimuno.com，并通过X、LinkedIn和Facebook与该公司联系。

Forward-Looking Statements

前瞻性声明

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”). Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “continue,” “believe,” “potential,” “upcoming” and other variations thereon and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statements.

本新闻稿包含1995年《私人证券诉讼改革法案》（“PSLRA”）所指的前瞻性声明。诸如“可能”、“将”、“预期”、“计划”、“预期”、“继续”、“相信”、“潜在”、“即将到来”等词语及其类似表达（以及其他引用未来事件或情况的词语或表达）旨在识别前瞻性陈述。

Many of these forward-looking statements involve a number of risks and uncertainties. Data, pre-clinical success and clinical success seen to date does not guarantee that Ampligen will be approved as a treatment or therapy for any diseases or conditions. The Company urges investors to consider specifically the various risk factors identified in its most recent Annual Report on Form 10-K, and any risk factors or cautionary statements included in any subsequent Quarterly Report on Form 10-Q or Current Report on Form 8-K, filed with the U.S.

这些前瞻性陈述中有许多涉及许多风险和不确定性。迄今为止所见的数据，临床前成功和临床成功并不保证Ampligen将被批准用于任何疾病或病症的治疗或治疗。公司敦促投资者特别考虑其最新10-K表年度报告中确定的各种风险因素，以及随后向美国提交的10-Q表季度报告或8-K表当前报告中包含的任何风险因素或警示声明。

Securities and Exchange Commission (the “SEC”). You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Among other things, for those statements, the Company claims the protection of the safe harbor for forward-looking statements contained in the PSLRA.

美国证券交易委员会（“SEC”）。提醒您不要过度依赖这些前瞻性声明，这些声明仅在本新闻稿发布之日起生效。除其他事项外，对于这些声明，该公司要求保护PSLRA中包含的前瞻性声明的安全港。

The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof..

公司不承诺更新任何前瞻性声明，以反映本协议日期后发生的事件或情况。。

Important Additional Information

重要附加信息

The Company, its directors and executive officers, Peter W. Rodino, III and Robert Dickey, IV, are deemed to be “participants” (as defined in Section 14(a) of the Securities Exchange Act of 1934, as amended) in the solicitation of proxies from the Company’s stockholders in connection with the Annual Meeting.

本公司及其董事和执行官Peter W.Rodino，III和Robert Dickey，IV被视为“参与者”（定义见1934年《证券交易法》第14（a）节，经修订）向本公司股东征集与年会有关的代理人。

The Company filed its definitive proxy statement (the “Definitive Proxy Statement”) and a WHITE universal proxy card with the SEC on November 4, 2024 in connection with such solicitation of proxies from the Company’s stockholders. STOCKHOLDERS OF THE COMPANY ARE STRONGLY ENCOURAGED TO READ SUCH DEFINITIVE PROXY STATEMENT, ACCOMPANYING WHITE UNIVERSAL PROXY CARD AND ALL OTHER DOCUMENTS FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY AS THEY CONTAIN IMPORTANT INFORMATION ABOUT THE ANNUAL MEETING.

公司于2024年11月4日向SEC提交了其最终委托书（“最终委托书”）和一张白色通用委托书卡，与公司股东的此类委托书征集有关。。

The Definitive Proxy Statement contains information regarding the identity of the participants, and their direct and indirect interests, by security holdings or otherwise, in the Company’s securities and can be found in the section titled “Principal Stockholders” of the Definitive Proxy Statement and available here.

最终委托书包含有关参与者身份的信息，以及他们在公司证券中通过证券持有或其他方式的直接和间接利益，可以在最终委托书标题为“主要股东”的部分中找到，并可在此处找到。

Information regarding subsequent changes to their holdings of the Company’s securities can be found in the SEC filings on Forms 3, 4, and 5, which are available on the Company’s website available here or through the SEC’s website at www.sec.gov. Stockholders will be able to obtain the Definitive Proxy Statement, any amendments or supplements thereto and other documents filed by the Company with the SEC at no charge at the SEC’s website at www.sec.gov.

有关其持有公司证券的后续变更的信息，请参阅表3、表4和表5中的SEC文件，这些文件可在公司网站上找到，也可以通过SEC网站www.SEC.gov获得。股东可以在SEC网站www.SEC.gov上免费获得最终委托书、其任何修订或补充以及公司向SEC提交的其他文件。

Copies will also be available at no charge at the Company’s website at https://aimimmuno.com/sec-filings/..

副本也将在公司网站上免费提供https://aimimmuno.com/sec-filings/..

1 See Modern Healthcare, Former pharma executives sue over firings (June 18, 2018).

1参见《现代医疗》，前制药高管因解雇而起诉（2018年6月18日）。

2 See Press Release issued by Rockwell Medical on May 24, 2018, available at: https://www.prnewswire.com/news-releases/rockwell-medical-issues-statement-300654699.html.

2见罗克韦尔医疗于2018年5月24日发布的新闻稿，网址：https://www.prnewswire.com/news-releases/rockwell-medical-issues-statement-300654699.html.